Seasonal Influenza in Primary Care Settings: Review for Primary Care Physicians

Jonathan L. Temte, MD, PhD; Jacob P. Prunuske, MD, MSPH

ABSTRACT
Context: Influenza is a common and significant respiratory pathogen in primary medical care. Better understanding of influenza epidemiology, clinical characteristics, prevention, and management is essential for effective ambulatory care.

Evidence Acquisition: Review of the current literature was performed through PubMed queries and based on the authors’ background and experience with influenza. In addition, summary data were presented from existing surveillance of influenza in Wisconsin.

Results: Seasonal influenza presents in annual epidemics with significant features of fever and cough. Prevention can be achieved through avoidance, influenza vaccine, and chemoprophylaxis. Diagnoses can be made on clinical grounds when appropriately supported by public health surveillance. Other diagnostic methods have limited use in primary care. Antiviral medications can have significant effects on illness course if started early, but may be limited by resistance.

Conclusions: Influenza is commonly prevented, diagnosed, and treated in the primary care arena. A combined approach to influenza response requires background knowledge on influenza epidemiology, prevention, diagnosis, and management, coupled with up-to-date information based on public health surveillance.

INTRODUCTION
Influenza is a significant and ubiquitous respiratory pathogen in humans. Despite great familiarity with this common infection, influenza never fails to surprise even the most seasoned observer. Primary care clinicians are on the front line for implementing influenza prevention and control efforts. An understanding of the basic concepts will enhance the primary care physician’s ability to better anticipate, provide prophylaxis against, and respond to seasonal and pandemic influenza, thereby contributing to public health efforts.

BASIC EPIDEMIOLOGY OF INFLUENZA
Influenza A and B viruses consist of 8 single strands of RNA enveloped in a lipid/glycoprotein membrane studded with 2 dominant and antigenic proteins. Hemagglutinin (H), with 16 known antigenic types in human influenza A, allows attachment of the virus to host respiratory mucosa. Neuraminidase (N), with 9 antigenic types, allows the budding and separation of newly formed influenza viruses from the host cell.

Antigenic Drift
Influenza A viruses are prone to mutation. Conversely, the genome of influenza B is more highly conserved. Mutations in the genes coding for either H or N proteins can alter their antigenic character. Slight to significant changes occur in surface antigens of influenza A viruses over time making antibodies formed during past infection or prior immunization for a given H or N antigen less effective. As a consequence, antigenic drift reduces previously acquired immunity, thus necessitating annual vaccination to adequately protect against circulating influenza viruses.

Antigenic Shift
Antigenic shift occurs with reassortment of 2 or more influenza A genomes within a host cell that is simultaneously infected. This shift can produce novel combinations of H and N, along with genetic material that can confer significant virulence and pathogenicity. A significant antigenic shift is accompanied by very low rates of naturally occurring immunity and sets the stage for pandemic spread of influenza.
Antigenic Gift
Influenza viruses have reservoirs within a wide variety of other mammalian and avian hosts, including domesticated animals such as swine and poultry. On occasion, influenza will jump species and produce significant human infection such as the smoldering avian influenza A(H5N1) zoonoses occurring in southeast Asia.

Transmission Characteristics
Like most respiratory viruses, influenza is spread from person to person through respiratory droplets. An individual with influenza can shed virus from 1 day before to 5-6 days after symptom onset. Peak shedding occurs with the peak of symptoms during day 2 or 3 of clinical illness. Prolonged shedding, however, can occur in patients hospitalized with severe disease.

Seasonality and Timing
Influenza is a highly seasonal virus with most transmission limited to late fall and winter across temperate latitudes. Cool, dry air facilitates transmission in laboratory studies. This results in peak influenza activity in late January and early February in the United States.

Pandemics of Influenza
Antigenic shifts or “gifts” (zoonoses) can result in the introduction of novel antigenic combinations for which there is no pre-existing immunity. Widespread and explosive outbreaks can occur at unexpected times of the year, circling the globe in a matter of weeks.

CLINICAL CONSEQUENCES OF INFLUENZA
Pathogenesis
After an incubation period averaging 1.4 days (range: 1-3 days), desquamation of infected respiratory mucosa and ciliated cells initiates early local symptoms. Interleukin-6 and interferon-α levels peak at 2 days correlating with mucus production, temperature, and symptom scores. This release of inflammatory cytokines results in the sudden onset of the pronounced malaise and fever characteristic of influenza infection.

Symptoms
Influenza-like illness (ILI) is defined as fever accompanied by a cough and/or sore throat. Influenza
symptoms are well defined and include fever, cough, malaise, headache, nasal congestion, sore throat, and myalgia (Figure 3).\textsuperscript{5,6,16} The positive predictive value of various clinical signs and symptoms generally support the use of fever with cough as an indicator of influenza illness when circulation has been confirmed in the community.\textsuperscript{17,18}

Consequences
Most individuals have mild to moderate symptoms and either continue with their daily activities or return to these after a short absence. Nevertheless, uncomplicated influenza infection can be associated with prolonged peripheral airway dysfunction and hyper-reactivity lasting up to 7 weeks.\textsuperscript{19} Emerging from numerous mild to moderate cases in the community are the estimated 226,000 annual influenza-related hospitalizations and 36,000 annual deaths.\textsuperscript{10} While attack rates are highest for older children, adolescents, and young adults, hospitalization and case fatality rates are highest for infants, young children, and older adults.\textsuperscript{10} The annual medical and indirect costs have been estimated at $10.4 billion and $76.7 billion, respectively.\textsuperscript{20}

PREVENTION OF INFLUENZA
Prevention is the key in managing influenza. Prevention can generally be accomplished in 3 ways: avoidance, vaccination, and chemoprophylaxis.

Avoidance
Avoiding exposure to respiratory droplets prevents infection (Box 1). Because influenza can survive on dry inanimate surfaces for 1-2 days,\textsuperscript{21} hand washing and the use of facemasks limit nosocomial spread by physicians and other health care workers (HCW) who often continue to work when infected with influenza.\textsuperscript{22} HCWs with influenza symptoms, however, should simply refrain from working since they interact with individuals at high risk for influenza complication. A recent randomized, controlled study detected no differences in the protection offered by simple surgical masks and N-95 respirators in hospital settings.\textsuperscript{23} Either soap and water or alcohol-based sanitizers are effective; antibacterial soaps are no more effective than standard products.\textsuperscript{24}

Immunization
Vaccines are developed annually in anticipation of the 3 strains of influenza [A(H1), A(H3) and B] that will most likely be in circulation during the coming influenza season.\textsuperscript{10} In addition, monovalent vaccines may be produced in response to pandemic threats such

**Box 1. Tips for Avoiding Influenza**

- Stay at least 3-6 feet away from sick people, farther if possible.
- Avoid touching your eyes, nose, or mouth, especially without washing your hands first.
- Stay away from crowded or confined spaces such as malls, subways, airplanes, or buses during influenza peaks.
- Avoid sharing food, drinking glasses, towels, or other personal care items with others.
- In the doctor’s office, keep your distance from other patients who may be ill.
- Use a facemask to reduce contact with respiratory droplets.
- Use a facemask to reduce spreading influenza if you are ill.
- Use a humidifier to increase humidity as influenza virus thrives in dry air.

**Additional Tips for Health Care Workers**

- Wash hands frequently.
- Get vaccinated as early as possible each year.
- Stay home if you have an influenza-like illness.

**Box 2. Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for the following individuals using an appropriate vaccine\textsuperscript{13}**

- Adults who want to reduce their risk of becoming ill with influenza or transmitting influenza to others
- All children 6 months to 18 years of age
- All adults ≥50 years of age
- Children and adolescents 6 months to 18 years of age receiving long-term aspirin therapy who might therefore be at risk for Reyes syndrome after influenza infection
- Women who will be pregnant during the influenza season
- Children, adolescents, and adults with chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, hematologic, or metabolic disorders (including diabetes mellitus)
- Children, adolescents, and adults who are immunosuppressed, including those receiving immunosuppressive drugs and those with HIV infection
- Children, adolescents, and adults with any condition that can compromise respiratory function or handling of respiratory secretions or increase the risk for aspiration (eg, cognitive dysfunction, spinal cord injuries, seizure disorders, other neuromuscular disorders)
- Children, adolescents, or adults who are residents of nursing homes and other chronic-care facilities
- Health care workers
- Household contacts and caregivers of children <5 years of age (especially contacts of children <6 months of age)
- Household contacts and caregivers of adults ≥50 years of age
- Household contacts and caregivers of individuals with medical conditions that put them at high risk for severe influenza complications
as for influenza A (H5N1) and influenza A (H1N1). Vaccination is now universally recommended by the Advisory Committee on Immunization Practices and is especially important for high-risk groups such as the elderly, pregnant women, and children. Influenza vaccination prevents death, hospitalization, and physician visits in high-risk patients. It is effective in elderly populations when the vaccine is well matched to the circulating influenza strains. Vaccination reduces influenza-like illness, pneumonia, hospital admission, and influenza or pneumonia-related deaths in nursing home patients, and reduces the risk of hospitalization for influenza or pneumonia and risk of death among community-dwelling elderly persons. Vaccinating physicians and staff who provide care to elderly patients in nursing homes may also reduce nursing home resident mortality from pneumonia and all cause death. Vaccine-induced immunity persists in elderly, supporting early vaccination timing.

In healthy adults, influenza vaccine reduces influenza and reduces work absence. Vaccination of pregnant women decreases respiratory illness in the mother and reduces influenza in infants during the first 6 months of life. Influenza vaccination of children in daycare or school may reduce morbidity in children and household contacts. Live attenuated influenza vaccine appears to be more effective than the trivalent inactivated vaccine in preventing influenza in children. Chemoprophylaxis

Chemoprophylaxis is an option for patients who have either not been vaccinated or have had exposure to influenza in the 2 weeks following vaccination. Prophylaxis should be continued for at least 10 to 14 days following exposure in home settings and at least 1 week past the end of an institutional outbreak.

The adamantane antivirals (amantadine and rimantadine) are active against influenza A; however, the Centers for Disease Control and Prevention (CDC) has advised not using adamantanes due to widespread resistance in A(H3) viruses. Adverse effects with adamantanes include insomnia, light-headedness, nervousness, difficulty concentrating, delirium, hallucinations, and seizures, but are less common with rimantadine.

The neuraminidase inhibitors (oseltamivir and zanamivir) are generally effective against influenza A and B and may be more effective than the adamantanes in preventing influenza, but resistance patterns need to be kept in mind. Adverse effects of oseltamivir include nausea, vomiting, and headache, while zanamivir is associated with nausea, vomiting, diarrhea, headache, respiratory tract irritation, and infection. Oseltamivir is FDA approved for children ≥1 year; reports of an association with adverse behavioral complications in children have not been confirmed in large cohort studies. In the 2008-2009 season, high resistance to oseltamivir in seasonal A(H1) viruses emerged. Zanamivir is FDA approved for children at least 5 years of age but is not recommended for patients with underlying airway disease. Oseltamivir, rimantadine, and amantadine doses must be adjusted for renal function.

CLINICAL MANAGEMENT OF INFLUENZA

Successful management of patients presenting with ILI depends on the clinician’s situational awareness, diagnostic approach, advice for supportive measures, and judicious use of antiviral medications. Awareness

Perhaps the greatest impediment to the appropriate management of influenza is the failure to recognize this common pathogen as a primary cause of fever and cough. This is evidenced by the 86-fold range in state-by-state estimates of H1N1 incidence during 2009. The key is awareness of community patterns of disease. Excellent surveillance information is available from the CDC (FluView: www.cdc.gov/flu/weekly), many state and local public health departments, and novel tools such as Google FluTrends (www.google.org/flu.trends).

Diagnosis

Diagnosis can be made on clinical grounds or through laboratory testing. Fever with cough in adults and children—when influenza is circulating in the community—is highly suggestive of influenza infection with a positive predictive value of 80%. Laboratory approaches include rapid antigen tests for influenza (RAI), direct fluorescent antibody testing (DFA), polymerase chain reaction (PCR), and culture. Of these, only RAI are applicable to the time constraints of ambulatory care. In a recent comparative study, 6 commercially available RAI had sensitivities of 67% to 71% for influenza A and 30% for influenza B. Specificities were uniformly high. Sensitivity, however, declines substantially with declining levels of virus in the respiratory mucosa indicating the importance of timing specimen collection relative to the course of illness.
Table 1. Antiviral Dosing for Prophylaxis and Treatment of Influenza

<table>
<thead>
<tr>
<th>Antiviral Agent</th>
<th>1-6</th>
<th>7-9</th>
<th>10-12</th>
<th>13-64</th>
<th>65 and Older</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zanamivir&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Treatment, influenza A and B</td>
<td>N/A&lt;sup&gt;b&lt;/sup&gt;</td>
<td>10 mg (2 inhalations) twice daily</td>
<td>10 mg (2 inhalations) twice daily</td>
<td>10 mg (2 inhalations) twice daily</td>
</tr>
<tr>
<td>Chemoprophylaxis, influenza A and B</td>
<td>Zanamivir Ages 1-4</td>
<td>N/A</td>
<td>10 mg (2 inhalations) once daily</td>
<td>10 mg (2 inhalations) once daily</td>
<td>10 mg (2 inhalations) once daily</td>
</tr>
<tr>
<td>Oseltamivir</td>
<td>Treatment&lt;sup&gt;c&lt;/sup&gt;, influenza A and B</td>
<td>Oseltamivir Ages 5-9</td>
<td>10 mg (2 inhalations) once daily</td>
<td>75 mg twice daily</td>
<td>75 mg twice daily</td>
</tr>
<tr>
<td>Chemoprophylaxis, influenza A and B</td>
<td>Oseltamivir Ages 5-9</td>
<td>Dose varies by child’s weight&lt;sup&gt;d&lt;/sup&gt;</td>
<td>75 mg/day</td>
<td>75 mg/day</td>
<td></td>
</tr>
<tr>
<td>Amanadine&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Treatment, influenza A</td>
<td>5 mg/kg body weight/day up to 150 mg in 2 divided doses&lt;sup&gt;f&lt;/sup&gt;</td>
<td>5 mg/kg body weight/day up to 150 mg in 2 divided doses&lt;sup&gt;f&lt;/sup&gt;</td>
<td>100 mg twice daily&lt;sup&gt;g&lt;/sup&gt;</td>
<td>100 mg twice daily&lt;sup&gt;g&lt;/sup&gt;</td>
</tr>
<tr>
<td>Prophylaxis, influenza A</td>
<td>Amanadine&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5 mg/kg body weight/day up to 150 mg in 2 divided doses&lt;sup&gt;f&lt;/sup&gt;</td>
<td>5 mg/kg body weight/day up to 150 mg in 2 divided doses&lt;sup&gt;f&lt;/sup&gt;</td>
<td>100 mg twice daily&lt;sup&gt;g&lt;/sup&gt;</td>
<td>≤100 mg/day</td>
</tr>
<tr>
<td>Rimantadine&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Treatment, influenza A</td>
<td>N/A</td>
<td>N/A</td>
<td>100 mg twice daily&lt;sup&gt;g&lt;/sup&gt;,&lt;sup&gt;k&lt;/sup&gt;</td>
<td>100 mg/day</td>
</tr>
<tr>
<td>Prophylaxis, influenza A</td>
<td>Rimantadine&lt;sup&gt;h&lt;/sup&gt;</td>
<td>5 mg/kg body weight/day up to 150 mg in 2 divided doses&lt;sup&gt;f&lt;/sup&gt;</td>
<td>5 mg/kg body weight/day up to 150 mg in 2 divided doses&lt;sup&gt;f&lt;/sup&gt;</td>
<td>100 mg twice daily&lt;sup&gt;g&lt;/sup&gt;</td>
<td>100 mg/day&lt;sup&gt;l&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Duration of Treatment: Recommended duration for antiviral treatment is 5 days.

Duration of Chemoprophylaxis: Recommended duration is 5-7 days after the last known exposure.

For control of outbreaks in long-term care facilities and hospitals, CDC recommends antiviral chemoprophylaxis for a minimum of 2 weeks and up to 1 week after the last known case was identified.

(http://www.cdc.gov/flu/professionals/antivirals/dosageTable.htm)

<sup>a</sup> Zanamivir is administered through oral inhalation by using a plastic device included in the medication package. Patients will benefit from instruction and demonstration of the correct use of the device. Zanamivir is not recommended for those persons with underlying airway disease.

<sup>b</sup> A reduction in the dose of oseltamivir is recommended for persons with creatinine clearance less than 30 mL/min.

<sup>c</sup> The treatment dosing recommendation for children who weigh <15 kg is 30 mg twice a day. For children who weigh >15 kg and up to 23 kg, the dose is 45 mg twice a day. For children who weigh >23 kg and up to 40 kg, the dose is 60 mg twice a day. For children who weigh >40 kg, the dose is 75 mg twice a day.

<sup>d</sup> The chemoprophylaxis dosing recommendation for children who weigh <15 kg is 30 mg once a day. For who weigh >15 kg and up to 23 kg, the dose is 45 mg once a day. For children who weigh >23 kg and up to 40 kg, the dose is 60 mg once a day. For children who weigh >40 kg, the dose is 75 mg once a day.

<sup>e</sup> The drug package insert should be consulted for dosage recommendations for administering amantadine to persons with creatinine clearance ≤50 mL/min/1.73m².

<sup>f</sup> 55 mg/kg body weight of amantadine or rimantadine syrup = 1 tsp/22 lbs.

<sup>g</sup> Children aged 10 years and older who weigh <40 kg should be administered amantadine or rimantadine at a dosage of 5 mg/kg body weight/day.

<sup>h</sup> A reduction in dosage to 100 mg/day of rimantadine is recommended for persons who have severe hepatic dysfunction or those with creatinine clearance <10 mL/min. Other persons with less severe hepatic or renal dysfunction taking 100 mg/day of rimantadine should be observed closely, and the dosage should be reduced or the drug discontinued, if necessary.

<sup>i</sup> Only approved by Food and Drug Administration (FDA) for treatment among adults.

<sup>j</sup> Not applicable.

<sup>k</sup> Rimantadine is approved by the FDA for treatment among adults. However, certain specialists in the management of influenza consider rimantadine appropriate for treatment among children. Studies evaluating the efficacy of amantadine and rimantadine in children are limited, but they indicate that treatment with either drug diminishes the severity of influenza A infection when administered within 48 hours of illness onset.

<sup>l</sup> Older nursing-home residents should be administered only 100 mg/day of rimantadine. A reduction in dosage to 100 mg/day should be considered for all persons aged 65 years and older, if they experience possible side effects when taking 200 mg/day.
dent and complicated by the emergence of resistant strains. Moreover, their use should be based on the potential benefits from treatment. In large meta-analyses, these medications reduce the length of influenza illness, on average, by approximately 1 day.48-53 For benefit, they have to be started within 36 to 48 hours of illness onset. Early initiation of therapy is associated with profound reductions in illness and return to full function.54 Initiation of therapy prior to a clinical visit—in selected patients—may provide 1 avenue for early intervention.55 There is emerging evidence that even antivirals started late in the course of hospitalized patient can reduce morbidity and mortality.56 The specific antivirals are discussed in the section on chemoprophylaxis; dosing is provided in Table 1. The adamantane antivirals are ineffective against influenza B viruses. Resistance to this antiviral class in influenza A(H3) viruses extended to 100% by 2009.37 Accordingly, adamantanes should be used only for seasonal A(H1) viruses. Widespread resistance to oseltamivir by seasonal influenza A(H1) viruses was also noted in 2009.42 Only zanamivir is effective against all strains of influenza, but is not recommended for children >7 years and in patients with respiratory problems such as asthma and chronic obstructive pulmonary disease (COPD).

The conundrum for the clinician, therefore, is choosing the correct antiviral therapy with insufficient information; there is no point-of-care test that will identify subtypes or resistance patterns. Consequently, empiric therapy must be based on up-to-date surveillance and a willingness to consider combination therapy (See Table 2).57 An example of a case of influenza presenting to the emergency department is available in Box 3.

**Box 3. Case Presentation**

In mid-March 2008, a 64-year-old man with a history of mild asthma presented to the emergency department (ED) of a hospital with complaints of progressive dyspnea and fever. He started feeling ill 24 hours ago after returning home from a cruise in Florida. In the ED, he was noted to have a temperature of 102.2°F. He was slightly tachycardic with a pulse rate of 104. Oxygen saturation on room air was 86%, rising to 96% with 2 liters/minute of oxygen per nasal cannula. A chest X-ray showed questionable hazy infiltrates. He was provided intravenous fluid and started on piperacillin/tazobactam by the ED physician for a presumptive pneumonia.

The admitting family physician noted the abrupt onset of symptoms, the lack of definitive consolidation on the chest X-ray (CXR), and the presence of an influenza-like illness during a period of circulation of multiple strains of influenza. A nasopharyngeal swab was obtained for influenza testing. Due to knowledge of circulating strains and antiviral resistance patterns, the family physician empirically started the patient on oseltamivir and amantadine.

By the following morning, the patient felt significantly improved. He no longer required oxygen. A direct fluorescent antibody test was positive for influenza A, and he was discharged to home that morning with a continuation of oseltamivir and amantadine for a total of 5 days.

**Supportive Measures**

Most authorities recommend rest, fluids, and antipyretics as supportive measures for influenza. Antipyretics can reduce fever and myalgia and make the patient feel subjectively better. A systematic review indicated benefit from acetaminophen and ibuprofen in the management of acute sore throat.47 Aspirin products should be avoided, especially in children, due to the risk of Reyes syndrome.

**Antiviral Medications**

Influenza antivirals can be effective in treating influenza infection, but their effectiveness is highly time depen-
PUBLIC HEALTH SURVEILLANCE OF INFLUENZA EPIDEMIOLOGY

There is a long history of partnerships between primary care clinicians, local and state public health departments, public health laboratories, and the CDC Influenza Branch, resulting in a highly functional, accurate, and timely monitoring of influenza. The US Outpatient Influenza-like Illness Surveillance Network (ILINet) started in 1974 as a cooperative agreement between the CDC and the Ambulatory Sentinel Physician Network. Over the years, this program has grown to be an essential component of influenza surveillance in the United States. When combined with virological surveillance, the ultimate product is highly accurate monitoring of influenza prevalence, strain assessment, and resistance patterns. Surveillance information available at www.cdc.gov/flu/weekly can assist the primary care clinician in making rational treatment decisions regarding patients presenting with fever and cough during the influenza season. Clinicians should also stay in close contact with their local and state health departments during the influenza season for a more detailed, local picture of influenza trends and recommendations.

Financial Disclosures: None declared.
Funding/Support: None declared.

REFERENCES


47. Thomas M, Del Mar C, Glasziou P. How effective are treatments other than antibiotics for acute sore throat? Br J Gen Pract. 2000;50:817-820.


The mission of the Wisconsin Medical Journal is to provide a vehicle for professional communication and continuing education of Wisconsin physicians.

The Wisconsin Medical Journal (ISSN 1098-1861) is the official publication of the Wisconsin Medical Society and is devoted to the interests of the medical profession and health care in Wisconsin. The managing editor is responsible for overseeing the production, business operation and contents of Wisconsin Medical Journal. The editorial board, chaired by the medical editor, solicits and peer reviews all scientific articles; it does not screen public health, socioeconomic or organizational articles. Although letters to the editor are reviewed by the medical editor, all signed expressions of opinion belong to the author(s) for which neither the Wisconsin Medical Journal nor the Society take responsibility. The Wisconsin Medical Journal is indexed in Index Medicus, Hospital Literature Index and Cambridge Scientific Abstracts.

For reprints of this article, contact the Wisconsin Medical Journal at 866.442.3800 or e-mail wmj@wismed.org.

© 2010 Wisconsin Medical Society